Providing a foundation, we present a summary of long‐term data derived from clinical trials, aiming to discern the effectiveness of anti‐PD‐1 antibodies or BRAF/MEK inhibitors in preventing recurrence and prolonging survival in melanoma patients. The gene discussed is MAP2K7; the disease is melanoma.